{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,13]],"date-time":"2026-03-13T13:33:17Z","timestamp":1773408797689,"version":"3.50.1"},"reference-count":12,"publisher":"Springer Science and Business Media LLC","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2024,10,18]]},"DOI":"10.7759\/cureus.71817","type":"journal-article","created":{"date-parts":[[2024,10,19]],"date-time":"2024-10-19T05:39:41Z","timestamp":1729316381000},"source":"Crossref","is-referenced-by-count":2,"title":["Ribociclib-Induced Autoimmune Hepatitis: A Case Report"],"prefix":"10.7759","author":[{"given":"Beyza","family":"Atay","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ali Berkcan","family":"Bozdogan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yigit","family":"Yazarkan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Muhammed Bahaddin","family":"Durak","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","reference":[{"key":"ref1","doi-asserted-by":"publisher","DOI":"10.1136\/bmj-2022-070201","article-title":"Diagnosis and management of autoimmune hepatitis","volume":"380","author":"Muratori L","year":"2023","unstructured":"Muratori L, Lohse AW, Lenzi M. Diagnosis and management of autoimmune hepatitis. BMJ. 2023, 380:e070201. 10.1136\/bmj-2022-070201","journal-title":"BMJ"},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.1002\/hep.23584","article-title":"Diagnosis and management of autoimmune hepatitis","volume":"51","author":"Manns MP","year":"2010","unstructured":"Manns MP, Czaja AJ, Gorham JD, Krawitt EL, Mieli-Vergani G, Vergani D, Vierling JM. Diagnosis and management of autoimmune hepatitis. Hepatology. 2010, 51:2193-213. 10.1002\/hep.23584","journal-title":"Hepatology"},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhep.2023.04.033","article-title":"Nomenclature, diagnosis and management of drug-induced autoimmune-like hepatitis (DI-ALH): An expert opinion meeting report","volume":"79","author":"Andrade RJ","year":"2023","unstructured":"Andrade RJ, Aithal GP, de Boer YS, et al.. Nomenclature, diagnosis and management of drug-induced autoimmune-like hepatitis (DI-ALH): An expert opinion meeting report. J Hepatol. 2023, 79:853-66. 10.1016\/j.jhep.2023.04.033","journal-title":"J Hepatol"},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.1007\/s11912-019-0769-3","article-title":"CDK 4\/6 inhibitors in breast cancer: current controversies and future directions","volume":"21","author":"Spring LM","year":"2019","unstructured":"Spring LM, Wander SA, Zangardi M, Bardia A. CDK 4\/6 inhibitors in breast cancer: current controversies and future directions. Curr Oncol Rep. 2019, 21:25. 10.1007\/s11912-019-0769-3","journal-title":"Curr Oncol Rep"},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1609709","article-title":"Ribociclib as first-line therapy for HR-positive, advanced breast cancer","volume":"375","author":"Hortobagyi GN","year":"2016","unstructured":"Hortobagyi GN, Stemmer SM, Burris HA, et al.. Ribociclib as first-line therapy for HR-positive, advanced breast cancer. N Engl J Med. 2016, 375:1738-48. 10.1056\/NEJMoa1609709","journal-title":"N Engl J Med"},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2018.78.9909","article-title":"Phase III randomized study of ribociclib and fulvestrant in hormone receptor-positive, human epidermal growth factor receptor 2-negative Aavanced breast cancer: MONALEESA-3","volume":"36","author":"Slamon DJ","year":"2018","unstructured":"Slamon DJ, Neven P, Chia S, et al.. Phase III randomized study of ribociclib and fulvestrant in hormone receptor-positive, human epidermal growth factor receptor 2-negative Aavanced breast cancer: MONALEESA-3. J Clin Oncol. 2018, 36:2465-72. 10.1200\/JCO.2018.78.9909","journal-title":"J Clin Oncol"},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.1002\/hep.23588","article-title":"Drug-induced autoimmune hepatitis: clinical characteristics and prognosis","volume":"51","author":"Bj\u00f6rnsson E","year":"2010","unstructured":"Bj\u00f6rnsson E, Talwalkar J, Treeprasertsuk S, et al.. Drug-induced autoimmune hepatitis: clinical characteristics and prognosis. Hepatology. 2010, 51:2040-8. 10.1002\/hep.23588","journal-title":"Hepatology"},{"key":"ref8","doi-asserted-by":"publisher","DOI":"10.1053\/j.gastro.2023.09.043","article-title":"A 68-year-old woman with unexplained liver enzyme elevation and active chronic hepatitis: beware of drug-induced autoimmune-like hepatitis","volume":"166","author":"Dara L","year":"2024","unstructured":"Dara L, Ghabril M, Phillips E, Kleiner D, Chalasani N. A 68-year-old woman with unexplained liver enzyme elevation and active chronic hepatitis: beware of drug-induced autoimmune-like hepatitis. Gastroenterology. 2024, 166:259-266.e1. 10.1053\/j.gastro.2023.09.043","journal-title":"Gastroenterology"},{"key":"ref9","doi-asserted-by":"publisher","DOI":"10.1016\/j.cgh.2016.05.043","article-title":"Features of autoimmune hepatitis in patients with drug-induced liver injury","volume":"15","author":"de Boer YS","year":"2016","unstructured":"de Boer YS, Kosinski AS, Urban TJ, et al.. Features of autoimmune hepatitis in patients with drug-induced liver injury. Clin Gastroenterol Hepatol. 2016, 15:103-112.e2. 10.1016\/j.cgh.2016.05.043","journal-title":"Clin Gastroenterol Hepatol"},{"key":"ref10","doi-asserted-by":"publisher","DOI":"10.1080\/0284186X.2020.1853228","article-title":"Hepatotoxicity associated with ribociclib among breast cancer patients","volume":"60","author":"Finnsdottir S","year":"2021","unstructured":"Finnsdottir S, Sverrisdottir A, Bj\u00f6rnsson ES. Hepatotoxicity associated with ribociclib among breast cancer patients. Acta Oncol. 2021, 60:195-8. 10.1080\/0284186X.2020.1853228","journal-title":"Acta Oncol"},{"key":"ref11","doi-asserted-by":"publisher","DOI":"10.1177\/10781552211027931","article-title":"A case report of fulminant hepatitis due to ribociclib with confirmed by liver biopsy in breast cancer","volume":"28","author":"Topcu A","year":"2022","unstructured":"Topcu A, Yasin AI, Shbair AT, et al.. A case report of fulminant hepatitis due to ribociclib with confirmed by liver biopsy in breast cancer. J Oncol Pharm Pract. 2022, 28:242-6. 10.1177\/10781552211027931","journal-title":"J Oncol Pharm Pract"},{"key":"ref12","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2023.1256783","article-title":"Ribociclib-induced liver injury: a case report","volume":"13","author":"Schaeffer S","year":"2023","unstructured":"Schaeffer S, Lutz C, Dobbie M, et al.. Ribociclib-induced liver injury: a case report. Front Oncol. 2023, 13:1256783. 10.3389\/fonc.2023.1256783","journal-title":"Front Oncol"}],"container-title":["Cureus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cureus.com\/articles\/297944-ribociclib-induced-autoimmune-hepatitis-a-case-report","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,10,19]],"date-time":"2024-10-19T05:39:42Z","timestamp":1729316382000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cureus.com\/articles\/297944-ribociclib-induced-autoimmune-hepatitis-a-case-report"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,10,18]]},"references-count":12,"URL":"https:\/\/doi.org\/10.7759\/cureus.71817","relation":{},"ISSN":["2168-8184"],"issn-type":[{"value":"2168-8184","type":"print"}],"subject":[],"published":{"date-parts":[[2024,10,18]]}}}